These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29614521)

  • 1. Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
    Peetermans M; Liesenborghs L; Peerlinck K; Wijngaerden EV; Gheysens O; Goffin KE; Hoylaerts MF; Jacquemin M; Verhaegen J; Peetermans WE; Verhamme P; Vanassche T;
    Thromb Haemost; 2018 May; 118(5):818-829. PubMed ID: 29614521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of staphylothrombin-mediated fibrin deposition in catheter-related Staphylococcus aureus infections.
    Vanassche T; Peetermans M; Van Aelst LN; Peetermans WE; Verhaegen J; Missiakas DM; Schneewind O; Hoylaerts MF; Verhamme P
    J Infect Dis; 2013 Jul; 208(1):92-100. PubMed ID: 23532100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation.
    Vanassche T; Kauskot A; Verhaegen J; Peetermans WE; van Ryn J; Schneewind O; Hoylaerts MF; Verhamme P
    Thromb Haemost; 2012 Jun; 107(6):1107-21. PubMed ID: 22437005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
    McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence.
    Vanassche T; Verhaegen J; Peetermans WE; VAN Ryn J; Cheng A; Schneewind O; Hoylaerts MF; Verhamme P
    J Thromb Haemost; 2011 Dec; 9(12):2436-46. PubMed ID: 22040101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
    Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
    Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
    Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
    J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban inhibits staphylothrombin.
    Hijikata-Okunomiya A; Kataoka N
    J Thromb Haemost; 2003 Sep; 1(9):2060-1. PubMed ID: 12941055
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
    He S; Wallèn H; Bark N; Blombäck M
    J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
    Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
    Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran inhibits Staphylococcus aureus coagulase activity.
    Vanassche T; Verhaegen J; Peetermans WE; Hoylaerts MF; Verhamme P
    J Clin Microbiol; 2010 Nov; 48(11):4248-50. PubMed ID: 20810780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.